Uncommon (1%) * Thrombocytopenia, i.e. can be associated with heparin-induced thrombocytopenia (0.5-5.0% of persons treated for at least five days) * Elevations in serum aminotransferases: 5.9%-6.1% * In people undergoing abdominal or colorectal surgery: * Bleeding, anemia, ecchymosis: ≥ 2% * In persons undergoing hip or knee replacement: * Fever, nausea, anemia, edema, peripheral edema: ≥ 2% * In persons with severely restricted mobility during acute illness: * Dyspnea, thrombocytopenia, confusion, diarrhea, nausea: ≥ 2% * In people being treated for deep vein thrombosis: * Injection site hemorrhage, injection site pain, hematuria: ≥ 2% Frequency under investigation * Local reactions: local irritation, pain, hematoma, ecchymosis, erythema * Bleeding * Hyperkalemia * Transaminitis * Hemorrhage Boxed warning The FDA issued a revision to the boxed warning for<unk>  in October 2013. The revision recommends exercising caution regarding when spinal catheters are placed and removed in persons taking<unk>  for spinal puncture or neuroaxial anesthesia. It may be necessary to delay anticoagulant dosing in these persons in order to decrease the risk for spinal or epidural hematomas, which can manifest as permanent or long-term paralysis. Persons at risk for hematomas may present with indwelling epidural catheters, concurrent use of medications that worsen bleeding states such as non-steroidal anti-inflammatory drugs (NSAIDs), or a past medical history of epidural or spinal punctures, spinal injury, or spinal deformations. The FDA recommends that at-risk persons be monitored for bleeding and neurological changes.
Enoxaparin sodium
Apixaban
Palladin
Dabigatran
Cilostazol
Ticlopidine
Rivaroxaban
Pitavastatin